<DOC>
	<DOCNO>NCT00651846</DOCNO>
	<brief_summary>The objective study investigate impact oral contraceptive YASMIN ( contain : drospirenone 3 mg/ethinyl estradiol 30 mcg ) comparison oral contraceptive MICROGYNON ( contain : levonorgestrel 150 mcg/ethinyl estradiol 30mcg ) factor blood coagulation fibrinolysis female subject</brief_summary>
	<brief_title>Investigate Impact Yasmin v Microgynon Hemostasis Parameters Healthy Women</brief_title>
	<detailed_description />
	<mesh_term>Hemostatics</mesh_term>
	<mesh_term>Ethinyl estradiol , levonorgestrel drug combination</mesh_term>
	<mesh_term>Ethinyl Estradiol-Norgestrel Combination</mesh_term>
	<mesh_term>Drospirenone ethinyl estradiol combination</mesh_term>
	<criteria>Clinically normal safety laboratory result Standard contraindication use combined oral contraceptive ( class label ) . Including : Presence history thromboembolic process vein ( deep venous thrombosis , pulmonary embolism ) artery ( e.g. , stroke , myocardial infarction ) know genetic component ( homozygous ) , venous thromboembolic event close relative ( parent sibling ) young age ( &lt; /= 40 year ) Acute chronic severe liver dysfunction disease . There interval least 6 month subsidence viral hepatitis ( normalization liver parameter ) start study medication . Use preparation experience show affect activity hepatic enzyme .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Contraception</keyword>
	<keyword>Hemostasis</keyword>
	<keyword>Blood Coagulation</keyword>
</DOC>